DMAC — DiaMedica Therapeutics Share News
0.000.00%
Last trade - 00:00- $513.37m
- $469.88m
DiaMedica Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview
DiaMedica Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
DiaMedica Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: DiaMedica Therapeutics Announces Publication Of Dm199’S Mechanism Of Action For The Treatment Of Acute Ischemic Stroke In The Journal Stroke
DiaMedica Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
DiaMedica Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Diamedica Therapeutics Announces Regulatory Approval To Begin Phase 2 Trial Of Dm199
DiaMedica Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
DiaMedica Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: DiaMedica Therapeutics Files For Resale Of Up To 4.7 Million Common - SEC Filing
Brief: Diamedica Therapeutics Announces $11.8 Million Private Placement
Brief: Diamedica Therapeutics Announces Expansion Of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
DiaMedica Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: DiaMedica Therapeutics Files For Mixed Shelf Offering Of Up To $100 Million - SEC Filing
U.S. RESEARCH ROUNDUP-Adobe, Microsoft, ServiceNow
Brief: Diamedica Therapeutics Says Co Has $53 Million Cash With Runway To 2026
Brief: Diamedica Therapeutics Appoints Dr. Lorianne Masuoka As Chief Medical Officer
DiaMedica Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Diamedica Therapeutics Appoints Ambarish Shah As Chief Technology Officer